公开(公告)号：KR1020170109274A

公开(公告)日：2017-09-29

申请号：KR1020160033161

申请日：2016-03-21

Applicant: 강원대학교산학협력단

Inventor： 이필호 ,  최원석

IPC: C07C313/06 ,  C07C311/05 ,  C07C311/18 ,  C07C303/36 ,  C07C303/42

Abstract: 본발명은리간드와카이랄보조제로사용되는중요한구조의성질을띄고있어다양한연구분야에서이용가능한신규의-이미도일설폭시민유도체및 이의제조방법에관한것으로, 보다상세하게는구리촉매존재하에알카인유도체, 아자이드유도체및 N-설폭시민유도체를반응시켜설폭시민의질소원자에탄소-질소결합작용기가도입된 N-이미도일설폭시민유도체를효율적으로제조하는방법및 이에따라제조된 N-이미도일설폭시민유도체에관한것이다.

Abstract translation: 本发明涉及新的在研究各个领域脱颖而出相关结构的特性可用于被用作配体狭手性助剂 - 约yimido一些帐户宽度铜催化剂下民间衍生物及其制造方法，更具体地，炔衍生物 ，叠氮化物衍生物，和N-亚砜反应的衍生物公民设定种子异喹啉氮原子制造的官能团的碳 - 氮键的方法是N- yimido某些帐户宽度民间衍生物有效地引入和yiettara制备N- yimido某些帐户宽度民间 ＆lt;

公开(公告)号：KR101845945B1

公开(公告)日：2018-04-05

申请号：KR1020160033161

申请日：2016-03-21

Applicant: 강원대학교산학협력단

Inventor： 이필호 ,  최원석

IPC: C07C313/06 ,  C07C311/05 ,  C07C311/18 ,  C07C303/36 ,  C07C303/42

Abstract: 본발명은리간드와카이랄보조제로사용되는중요한구조의성질을띄고있어다양한연구분야에서이용가능한신규의-이미도일설폭시민유도체및 이의제조방법에관한것으로, 보다상세하게는구리촉매존재하에알카인유도체, 아자이드유도체및 N-설폭시민유도체를반응시켜설폭시민의질소원자에탄소-질소결합작용기가도입된 N-이미도일설폭시민유도체를효율적으로제조하는방법및 이에따라제조된 N-이미도일설폭시민유도체에관한것이다.

公开(公告)号：KR101228381B1

公开(公告)日：2013-01-31

申请号：KR1020110031169

申请日：2011-04-05

Applicant: 강원대학교산학협력단

Inventor： 이필호 ,  박영철 ,  최원석 ,  김철의 ,  박미선 ,  김성각

IPC: C07C45/61 ,  C07C49/537 ,  C07C69/753 ,  C07D307/80

Abstract: 본 발명은 철 촉매를 이용하여 α-알키닐 β-케토에스터 화합물의 분자내 고리화 반응을 통하여 온화한 조건하에서 보다 간단한 방법을 통해 높은 수율로 5각고리 화합물을 합성하는 제조방법을 제공한다.

公开(公告)号：KR101448582B1

公开(公告)日：2014-10-13

申请号：KR1020140053257

申请日：2014-05-02

Applicant: 강원대학교산학협력단

Inventor： 이필호 ,  신서현 ,  강동진 ,  엄다한 ,  김예린 ,  정연석 ,  최원석

IPC: C07F9/6571 ,  C07B41/00

CPC classification number: C07F9/657181 ,  C07F9/657172 ,  C07F9/65744

Abstract: The present invention relates to a novel cyclic phosphinate derivative and a preparing method thereof, and more specifically the cyclic phosphinate derivative of the present invention comprises a benzooxaphosphole oxide derivative and a benzooxaphosphorine oxide derivative. The cyclic phosphinate derivative of the present invention has pharmacological activity and bioactivity, and can be used in novel drug development and synthesis of various pharmaceuticals as well as used as a basic structure of natural materials. In addition, the method for preparing the cyclic phosphinate derivative according to the present invention has strong points of preparing various cyclic phosphinate derivatives having high yield through a simple synthesizing process by conducting intramolecular carbon-oxygen coupling reaction of a phosphonic acid derivative with a palladium (Pd) catalyst, an oxidizing agent and a base.

Abstract translation: 本发明涉及一种新型的环状次膦酸酯衍生物及其制备方法，更具体地说，本发明的环状次膦酸酯衍生物包含苯并氧磷杂环磷酸酯衍生物和苯氧基磷氧化物衍生物。 本发明的环状次膦酸酯衍生物具有药理活性和生物活性，可用于各种药物的新药开发和合成，也可用作天然物质的基本结构。 此外，本发明的环状次膦酸酯衍生物的制备方法通过简单的合成方法通过使膦酸衍生物与钯的分子内碳 - 氧偶联反应来制备具有高收率的各种环状次膦酸酯衍生物的优点（ Pd）催化剂，氧化剂和碱。

公开(公告)号：KR1020120113453A

公开(公告)日：2012-10-15

申请号：KR1020110031169

申请日：2011-04-05

Applicant: 강원대학교산학협력단

Inventor： 이필호 ,  박영철 ,  최원석 ,  김철의 ,  박미선 ,  김성각

IPC: C07C45/61 ,  C07C49/537 ,  C07C69/753 ,  C07D307/80

Abstract: PURPOSE: A method for manufacturing pentacyclic compound using a simple method through intracyclization reaction of A-alkynyl B-ketoester compound are provided to manufacture the pentacyclic compound at high yield. CONSTITUTION: A method for manufacturing pentacyclic compound includes a step of manufacturing the pentacyclic compound represented by chemical formula 1 under the presence of an iron catalyst. In the chemical formula 1 or 5, R is selected from C1-C7 alkyl, C3-C8 cycloalkyl, C6-C20 aryl, or C3-C20 heteroaryl. R^1 is selected from C6-C20 arylamino and the C1-C7 alkoxy. R^2 is selected from hydrogen, C1-C7 alkyl or C6-C20 aryl.

Abstract translation: 目的：提供使用简单方法通过α-炔基B-酮酯化合物的内环化反应制备五环化合物的方法，以高产率制备五环化合物。 构成：制备五环化合物的方法包括在铁催化剂存在下制备由化学式1表示的五环化合物的步骤。 在化学式1或5中，R选自C 1 -C 7烷基，C 3 -C 8环烷基，C 6 -C 20芳基或C 3 -C 20杂芳基。 R 1选自C 6 -C 20芳基氨基和C 1 -C 7烷氧基。 R 2选自氢，C 1 -C 7烷基或C 6 -C 20芳基。

公开(公告)号：KR1020140102811A

公开(公告)日：2014-08-25

申请号：KR1020130016130

申请日：2013-02-15

Applicant: 강원대학교산학협력단

Inventor： 정유진 ,  최원석 ,  우윤서 ,  조정현

IPC: A61K31/437 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention relates to a use of imiquimod as an adjuvant for cancer treatment. The inventors have revealed that imiquimod, which is a stimulator of TLR7, promotes apoptosis by causing self-predation by the generation of free radicals in a result of treating the imiquimod to liver cancer, melanoma cancer, and chemotherapy resistant melanoma cancer that have resistance to anticancer agents for colon cancer and EGFR over-expressed colon cancer. Therefore, the imiquimod can be used as an adjuvant for cancer treatment for chemotherapy resistant cancer.

Abstract translation: 本发明涉及咪喹莫特作为癌症治疗佐剂的用途。 本发明人已经揭示了作为TLR7刺激剂的咪喹莫特通过在将咪喹莫特治疗到具有耐药性的肝癌，黑素瘤癌症和抗化学药物的黑素瘤癌症的结果中引起自由基的产生而促进凋亡 抗癌剂用于结肠癌和EGFR过表达结肠癌。 因此，咪喹莫特可以用作化疗耐药性癌症的癌症治疗佐剂。